Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats

Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1175-84. doi: 10.1152/ajpregu.00238.2007. Epub 2008 Feb 6.

Abstract

Luminal nutrients stimulate structural and functional regeneration in the intestine through mechanisms thought to involve insulin-like growth factor I (IGF-I) and glucagon-like peptide-2 (GLP-2). We investigated the relationship between IGF-I and GLP-2 responses and mucosal growth in rats fasted for 48 h and then refed for 2 or 4 days by continuous intravenous or intragastric infusion or ad libitum feeding. Fasting induced significant decreases in body weight, plasma concentrations of IGF-I and bioactive GLP-2, jejunal mucosal cellularity (mass, protein, DNA, and villus height), IGF-I mRNA, and ileal proglucagon mRNA. Plasma IGF-I concentration was restored to fed levels with 2 days of ad libitum refeeding but not with 4 days of intravenous or intragastric refeeding. Administration of an inhibitor of endogenous GLP-2 (rat GLP-2 3-33) during ad libitum refeeding partially attenuated mucosal growth and prevented the increase in plasma IGF-I to fed levels; however, plasma GLP-2 and jejunal IGF-I mRNA were restored to fed levels. Intragastric refeeding restored intestinal cellularity and functional capacity (sucrase activity and sodium-glucose transporter-1 expression) to fed levels, whereas intravenous refeeding had no effect. Intestinal regeneration after 4 days of intragastric or 2 days of ad libitum refeeding was positively associated with increases in plasma concentrations of GLP-2 and jejunal IGF-I mRNA. These data suggest that luminal nutrients stimulate intestinal growth, in part, by increased expression of both GLP-2 and IGF-I.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adaptation, Physiological
  • Animals
  • Body Weight
  • Dose-Response Relationship, Drug
  • Eating*
  • Fasting / blood*
  • Glucagon-Like Peptide 2 / antagonists & inhibitors
  • Glucagon-Like Peptide 2 / blood
  • Glucagon-Like Peptide 2 / metabolism*
  • Glucagon-Like Peptide 2 / pharmacology
  • Ileum / drug effects
  • Ileum / growth & development
  • Ileum / metabolism*
  • Infusions, Intravenous
  • Insulin / blood
  • Insulin-Like Growth Factor Binding Protein 3 / metabolism
  • Insulin-Like Growth Factor Binding Protein 5 / metabolism
  • Insulin-Like Growth Factor I / genetics
  • Insulin-Like Growth Factor I / metabolism*
  • Intestinal Mucosa / growth & development
  • Intestinal Mucosa / metabolism
  • Intubation, Gastrointestinal
  • Jejunum / drug effects
  • Jejunum / enzymology
  • Jejunum / growth & development
  • Jejunum / metabolism*
  • Male
  • Nitrogen / metabolism
  • Parenteral Nutrition*
  • Peptide Fragments / pharmacology
  • Proglucagon / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Regeneration*
  • Sodium-Glucose Transporter 1 / metabolism
  • Sucrase / metabolism
  • Time Factors

Substances

  • Glucagon-Like Peptide 2
  • Insulin
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor Binding Protein 5
  • Peptide Fragments
  • RNA, Messenger
  • Slc5a1 protein, rat
  • Sodium-Glucose Transporter 1
  • glucagon-like peptide-2 (3-33)
  • Proglucagon
  • Insulin-Like Growth Factor I
  • Sucrase
  • Nitrogen